Huntington's Disease - Drug Pipeline Analysis and Market Forecasts to 201626 Mar 2010 • by Natalie Aster
GlobalData’s report, “Huntington’s Disease - Drug Pipeline Analysis and Market Forecasts to 2016”, is an essential source of information and analysis on the global Huntington’s disease market. The report identifies the key trends shaping and driving the global Huntington’s disease market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global Huntington’s disease sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
The Huntington’s Disease Market is Forecast to Show High Growth Until 2016
The global Huntington’s disease (HD) market was worth $243m in 2009. The market is expected to grow by 17.4% during the next seven years to reach $748m by 2016. Earlier, the HD therapeutics market was underserved due to the lack of an approved medication and the use conventional antipsychotics and antiepileptics. Biovail’s Xenazine, approved in November 2008, is the first approved treatment option for the chorea (uncontrolled movements) associated with HD. The pipeline has a few promising molecules which are expected to launch in the near future. If approved, the upcoming therapies will compete with Xenazine, leading to a market share war. Xenazine will be the primary driver for the HD market until the launch of any late stage pipeline molecules. Essentially, the global HD market is heading towards a phase of continuous growth, leveraging the current opportunities.
Competition in the Huntington’s Disease Market is Weak
GlobalData analyzed and found the current competition in the HD market to be weak. The market is underserved with only one approved product, Xenazine, which was the first approved drug to enter the HD market for the treatment of the chorea associated with HD. Although Xenazine failed to serve the market as a curative therapy, it has shown a positive uptake. While the market remains underserved by current therapies, the newer candidates will have substantial scope for growth and profitability. Antipsychotics and antiepileptics are the most widely prescribed treatment options for HD. Xenazine has been successful in leveraging the untapped potential of the market. The competition is anticipated to be fierce, with the launch of late stage pipeline molecules which will lead to market share war.
Current Treatment Options Do Not Cater to the Existing Unmet Need
GlobalData found that there are limited treatment options that leave behind a substantial segment of unmet need. The available treatments do not meet the current market requirements for safety and efficacy. Xenazine has been accepted as the first drug approved for the treatment of chorea in HD. Since it has orphan drug status and has been priced at premium, affordability will be a decisive factor for its sustained uptake. The market is in need of neuroprotective agents which could slow disease progression and increase the survival rate. The late stage pipeline seems to offer better products that would leverage the hidden potential in the HD market. The market in the near future is expected to be sufficed by more efficacious and safer products that can compete with the existing drugs. These can target the unmet need existing in the market.
Improved Diagnostic Tests Uncover Presymptomatic Huntington’s Disease
HD is of genetic origin and is inherited from the parent affected with a mutated Huntingtin (HTT) gene. The child of infected parent has 50% risk of developing the symptoms of the disease. This genetic link has been quite well understood and the appropriate genetic tests have been devised to diagnose HD. Along with this, a neurological examination is also conducted to outweigh the possible errors. This has lead to the diagnosis of presymptomatic patients so that adequate measures can be taken and the survival period can be extended. An increase in the numbers of pre- and post-symptomatic patients being diagnosed has encouraged companies to conduct clinical research into discovering the cure for HD. Though the current market does not offer any significant treatment for HD, it does provide the efficient management of symptoms. Safety and pricing are the two major concerns with the currently available HD treatment. Since there are limited options for the treatment of HD, pipeline drugs with better safety, affordability, increased patient compliance and efficacy profiles are likely to achieve blockbuster status.
Strong Pipeline to Alter the Course of Huntington’s Disease in the Near Future
GlobalData’s pipeline analysis revealed that there are more than 24 molecules in the pipeline that are spread across the various stages of clinical development. Phase III is considered to be the most promising stage, with four molecules. Phase II has six pipeline molecules. There are only three molecules in Phase I and a large number in the preclinical stage. AMR-101 from Amarin is expected to be a promising candidate for HD. A majority of the pipeline molecules have a novel mechanism of action and are efficient in the respective target areas as outlined by their clinical study results. Companies have been successful in gaining support and sponsorships from different government bodies such as the Huntington’s Study Group (HSG), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institutes of Health (NIH) and the Huntington’s Disease Society of America (HDSA) for conducting clinical studies on molecules expected to provide treatment for HD. There are huge commercialization opportunities for the near future owing to a strong pipeline. Newer therapies therefore need to compete with Xenazine in order to be successful in the HD therapeutics market.
GlobalData is an industry analysis specialist company providing business information products and services.
Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.